Other News

Clinical Trial Results from MyoKardia’s Phase 2 PIONEER-HCM Study of Mavacamten Published in the Annals of Internal Medicine

SOUTH SAN FRANCISCO, Calif., April 30, 2019 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced the publication of results from the company’s Phase 2 PIONEER-HCM study of mavacamten in an upcoming issue of […]

Precision Optics Corporation, Inc. Announces Receipt of $2.2 Million Order For Custom Designed Cardiovascular Endoscope

GARDNER, Mass., April 29, 2019 (GLOBE NEWSWIRE) — Precision Optics Corporation, Inc. (OTCQB: PEYE) today announced that it has received a follow-on order totaling $2,216,000 from CardioFocus, Inc. for the manufacture of a cardiovascular endoscope to support the HeartLight Endoscopic Ablation System. Deliveries are scheduled to be made over two […]

Dr. Mary Norine Walsh Joins SOLVE CRT Clinical Study as Co-Principal Investigator

SUNNYVALE, Calif., April 30, 2019 /PRNewswire/ — EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, today announced that Dr. Mary Norine “Minnow” Walsh has become Co-Principal Investigator (Co-PI) of the SOLVE CRT clinical study. The SOLVE CRT (Stimulation of the Left Ventricular Endocardium for Cardiac […]

Ablacon, Inc. Raises $21.5M Series A to Advance AI-Enabled Atrial Fibrillation Mapping System

MENLO PARK, Calif., April 30, 2019 /PRNewswire/ — Ablacon, Inc. (www.ablacon.com), a Wheat Ridge, CO-based company developing an advanced mapping system to guide the treatment of atrial fibrillation (AFib), today announced the closing of a $21.5 million Series A financing round led by Ajax Health.  Ablacon’s novel algorithm uses artificial intelligence (AI) to analyze and visualize […]

Medtronic Announces U.S. Commercial Launch of Solitaire(TM) X Revascularization Device

DUBLIN – April 30, 2019 – Medtronic plc (NYSE:MDT) today announced the U.S. launch of the Solitaire(TM) X Revascularization Device – and its first use in patients for the treatment of acute ischemic stroke. For ten years, the industry-leading Solitaire(TM) Revascularization Device has enabled physicians in helping patients have a better […]

OPSENS SIGNS LANDMARK SUPPLIER AGREEMENT – EXPANDS OPTICAL SENSING TECHNOLOGY IMPACT WITHIN CARDIOLOGY SEGMENT

Quebec City, Quebec, April 30, 2019 – Opsens inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) is pleased to announce it has entered into a supply agreement as part of its long-term collaboration with Abiomed, Inc. (“Abiomed”) for the Impella CP® heart pump. Abiomed has awarded Opsens a five-year agreement to supply […]

New Study Finds Abbott Blood Test Can Help Predict Future Cardiac Events in Adults with No Known Heart Disease

ABBOTT PARK, Ill., April 29, 2019 /PRNewswire/ — Abbott (NYSE: ABT) announced today that a new study published in Circulation found its High Sensitive Troponin-I blood test could predict the chance of developing a cardiac event years before it occurs in people with no symptoms when added to current heart disease assessments.1 Using data from the Atherosclerosis […]

Endonovo Therapeutics Provides Corporate Update

LOS ANGELES, CA, April 26, 2019 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), a commercial-stage developer of non-invasive Electroceutical™ therapeutic devices, today announced a corporate update and business plan for the remainder of 2019. Revenue projections for the first quarter ended March 31, 2019 are expected to […]

Quantum Genomics Announces the Publication of its Phase IIb NEW-HOPE Study Results of Firibastat in Arterial Hypertension in the Journal Circulation

PARIS and NEW YORK, April 26, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant hypertension and heart failure, announces the publication of the full results from its Phase […]